-
Limiting babies’ sugar intake protects them against chronic diseases Nat. Med. (IF 58.7) Pub Date : 2024-11-20
Post-war rationing in the UK in 1953 facilitated a natural experiment that now reveals that restricting sugar intake in early life reduces the risk of diabetes and hypertension.
-
UNRWA's work is at risk again Lancet (IF 98.4) Pub Date : 2024-11-20 Bassam Abu Hamad, Zeina Jamaluddine, Sarah Aly, Mohammad Salayma, Yara Asi, Hani Mowafi, Francesco Checchi, Miho Sato, Asli Bali, Paul Spiegel
No Abstract
-
Editorial Expression of Concern: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nat. Med. (IF 58.7) Pub Date : 2024-11-20 Angela Nebbioso, Nicole Clarke, Emilie Voltz, Emmanuelle Germain, Concetta Ambrosino, Paola Bontempo, Rosana Alvarez, Ettore M. Schiavone, Felicetto Ferrara, Francesco Bresciani, Alessandro Weisz, Angel R. de Lera, Hinrich Gronemeyer, Lucia Altucci
Addendum to: Nature Medicine https://doi.org/10.1038/nm1161, published online 26 December 2004.
-
Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation BMJ (IF 93.6) Pub Date : 2024-11-19 Elie A Akl, Joanne Khabsa, Claire Iannizzi, Vanessa Piechotta, Lara A Kahale, James M Barker, Joanne E McKenzie, Matthew J Page, Nicole Skoetz
Publications of living systematic reviews (LSRs) are increasing rapidly. Guidance facilitating transparent, complete, and accurate reporting of LSRs is needed. This paper reports the development of an extension of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement for LSRs (PRISMA-LSR). The PRISMA-LSR extension includes the PRISMA-LSR checklist, the PRISMA-LSR
-
Helen Salisbury: Neighbourhood teams are disintegrating—to make them work, we need more staff BMJ (IF 93.6) Pub Date : 2024-11-19 Helen Salisbury
The aim of an integrated neighbourhood team (INT) is to bring medical, nursing, and social care services to the patient’s home (or nearby) in a timely fashion, which should prevent unnecessary hospital admissions and enable earlier discharge, thus saving the NHS money and minimising disruption for patients. These ideas seem so obvious that it’s hard to work out why they haven’t been tried before. They
-
Conflicts of interest: moving towards zero tolerance BMJ (IF 93.6) Pub Date : 2024-11-19 Chris van Tulleken, Nigel Rollins, Rebecca Coombes
Harmful industries still exert their influence over health professionals, academia, and health systems; robust change is required, write Chris van Tulleken, Nigel Rollins, and Rebecca Coombes In the 1950s, smoking was proven beyond doubt to cause cancer and yet efforts to curb this pandemic were stalled over the next half century by a network of individuals and institutions with competing interests
-
Matt Morgan: Don’t lose the “why” BMJ (IF 93.6) Pub Date : 2024-11-20 Matt Morgan
A ward round in the intensive care unit ended with more questions than answers for the team. Only after seeing 10 critically ill patients did the hard work start: it was clear what was needed to help patients survive, but working out the “why” was more difficult. We knew that we needed to start steroids in a patient with septic shock—but why? We quickly decided that a patient recovering from a brain
-
David Oliver: We should welcome Labour’s proposed 10 year NHS plan with healthy scepticism BMJ (IF 93.6) Pub Date : 2024-11-20 David Oliver
When Labour came to power in July the new health and social care secretary, Wes Streeting, promised a frank report on the current NHS. The report, led by Ara Darzi, pulled no punches about the state of the service and its challenges,12 which led Streeting to say that the NHS was “broken.”3 He also promised a working group to report back next spring on a 10 year plan.4 I want the Labour government to
-
Climate crisis imperils the fabric of life: GMC must review its policies BMJ (IF 93.6) Pub Date : 2024-11-19 Alexander J K Wilkinson, Laura-Jane Smith, Frances Mortimer
The General Medical Council emphasises the relevant policies and laws it must follow,1 but tremendous injustices can be committed by unthinkingly “following procedure.” Extraordinary circumstances provide important opportunities to reflect on whether policies remain fit for purpose. The GMC shouldn’t judge the fairness of a law, but it must decide if public trust is damaged when laws are broken. If
-
Fatigue risks from working in the NHS BMJ (IF 93.6) Pub Date : 2024-11-20 Bernadette Dalton
I agree with Moreno that society needs a new perspective on time.1 A 24 h workforce is “productivity driven,” a functional necessity embedded in NHS practice. It follows that irregular sleep schedules and sleep deficiency are controlled by commercial actors.2 Seeking to affect policies at all levels of governance, through systems, practices, and pathways,3 commercial determinants influence …
-
How patients are using AI BMJ (IF 93.6) Pub Date : 2024-11-19 Chris Stokel-Walker
Artificial intelligence (AI) tools such as ChatGPT have hundreds of millions of users—but are they medically safe and reliable? Chris Stokel-Walker asks patients and physicians about the benefits and risks in an AI world In August this year Hayley Brackley lost a large part of her vision, completely out of the blue. She’d gone to her local chemist with eye pain, and a prescribing pharmacist diagnosed
-
Road safety in Africa: a preventable public health crisis BMJ (IF 93.6) Pub Date : 2024-11-19 H I Geduld, P Kinyanjui
Health, economic, and social progress will stall without urgent global collaborative action Road traffic injuries are the leading killer of children and adults aged 5-29 years globally.1 Low and middle income countries are disproportionately represented in this statistic; Africa has the highest road crash mortality of all global regions. Increasing urbanisation and motorisation in many African countries
-
Fragile promise of psychedelics in psychiatry BMJ (IF 93.6) Pub Date : 2024-11-19 Cédric Lemarchand, Raphaël Chopin, Morgane Paul, Alain Braillon, Lisa Cosgrove, Ioana Cristea, Eiko I Fried, Erick H Turner, Florian Naudet
Cédric Lemarchand and colleagues highlight weaknesses in the evidence on efficacy and safety of hallucinogens and question the use of expedited regulatory pathways The US clinical market for ketamine, estimated at $3.1bn in 2022 and expected to expand at 10.6% a year until 2030,1 is just one of many signs of renewed interest in the use of psychedelics to treat psychiatric conditions.2 Various mind
-
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S) Lancet (IF 98.4) Pub Date : 2024-11-19 Timo E Strandberg, Petri T Kovanen, Donald M Lloyd-Jones, Frederick J Raal, Raul D Santos, Gerald F Watts
Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor for atherosclerotic cardiovascular disease. Safe and effective statins remain the cornerstone of therapeutic approach for this indication, including for children with genetic dyslipidaemia, and are one
-
The cost of not investing in the next 1000 days: implications for policy and practice Lancet (IF 98.4) Pub Date : 2024-11-18 Milagros Nores, Claudia Vazquez, Emily Gustafsson-Wright, Sarah Osborne, Jorge Cuartas, Mark J Lambiris, Dana C McCoy, Florencia Lopez-Boo, Jere Behrman, Raquel Bernal, Catherine E Draper, Anthony D Okely, Mark S Tremblay, Aisha K Yousafzai, Joan Lombardi, Günther Fink
Building on the evidence from the first paper in this Series highlighting the fundamental importance of healthy and nurturing environments for children's growth and development in the next 1000 days (ages 2–5 years), this paper summarises the benefits and costs of key strategies to support children's development in this age range. The next 1000 days build on the family-based and health-sector based
-
The first and next 1000 days: a continuum for child development in early life Lancet (IF 98.4) Pub Date : 2024-11-18 Victor M Aguayo, Pia R Britto
No Abstract
-
The next 1000 days: building on early investments for the health and development of young children Lancet (IF 98.4) Pub Date : 2024-11-18 Catherine E Draper, Aisha K Yousafzai, Dana C McCoy, Jorge Cuartas, Jelena Obradović, Sunil Bhopal, Jane Fisher, Joshua Jeong, Sonja Klingberg, Kate Milner, Lauren Pisani, Aditi Roy, Jonathan Seiden, Christopher R Sudfeld, Stephanie V Wrottesley, Günther Fink, Milagros Nores, Mark S Tremblay, Anthony D Okely
Following the first 1000 days of life that span from conception to two years of age, the next 1000 days of a child's life from 2–5 years of age offer a window of opportunity to promote nurturing and caring environments, establish healthy behaviours, and build on early gains to sustain or improve trajectories of healthy development. This Series paper, the first of a two-paper Series on early childhood
-
Celebrating Alessandro Liberati, his vision, books, journals, libraries, “anti libraries,” and radical thinking BMJ (IF 93.6) Pub Date : 2024-11-18 Nicola Magrini, Luca de Fiore, Richard Smith
The football-loving medical philosopher, founder of the Italian Cochrane Centre, and former member of the BMJ editorial board Alessandro Liberati died 12 years ago, but he was remembered with great fondness earlier this year when Mariangela, his wife, donated almost 150 of his books to the hospital library of Reggio Emilia Arcispedale, one of the finest and best restored medical libraries in Italy
-
John Launer: The dilemma of private care BMJ (IF 93.6) Pub Date : 2024-11-19 John Launer
Like many people, I can no longer find effective dental treatment locally on the NHS. Against my personal preference and political views, I’ve been to a private dentist for some years now. He’s a decent man, charges relatively modest prices, and is conservative (in the best sense) in his interventions. We banter nicely about my need for elephantine quantities of local analgesia, as well as other matters
-
David Watkin: General surgeon who improved surgical training and helped establish the Leicester Medical School BMJ (IF 93.6) Pub Date : 2024-11-19 Sally Watkin
David Watkin was a firm believer in the importance of teaching, but he felt that the training he received was inadequate. “The number of operations for which a consultant directly supervised me could be counted on the fingers of one hand,” he wrote. He worked tirelessly to do better for his staff—and not just doctors and medical students. Shortly after taking up his consultant post in general surgery
-
There is no point waiting for COP29 BMJ (IF 93.6) Pub Date : 2024-11-19 David McKelvey
Mulcahy and Smith clearly detail the failure of the United Nations climate change conference (COP) process.1 As they point out, despite all the meetings, emissions still rise. If you plot the rise in CO2 emissions since COP meetings began, you might be forgiven for wondering if they have caused the rise in emissions, or at …
-
Defending our colleagues who take direct action on climate change BMJ (IF 93.6) Pub Date : 2024-11-19 Milo J A Simpson
Hoyle and Yassaie discuss whether doctors should be suspended for breaking the law.1 We are, of course, currently on track to face catastrophic warming caused by fossil fuels. Globally, the scientific community is sounding the alarm. The cost to public …
-
Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Nat. Med. (IF 58.7) Pub Date : 2024-11-17 Barry A. Borlaug, Michael R. Zile, Christopher M. Kramer, Seth J. Baum, Karla Hurt, Sheldon E. Litwin, Masahiro Murakami, Yang Ou, Navneet Upadhyay, Milton Packer
-
Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial BMJ (IF 93.6) Pub Date : 2024-11-18 Katrin Schaudig, Xuegong Wang, Céline Bouchard, Angelica Lindén Hirschberg, Antonio Cano, Marla Shapiro C M, Petra Stute, Xi Wu, Kentaro Miyazaki, Ludmila Scrine, Rossella E Nappi
Objectives To assess the efficacy and safety of the non-hormonal, neurokinin 3 receptor antagonist, fezolinetant, to treat moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy. Design Phase 3b randomised controlled trial. Setting 16 countries. Participants 453 individuals aged 40-65 years with moderate-severe vasomotor symptoms associated with menopause
-
Brazil’s G20 leadership offers glimmers of hope for global health equity BMJ (IF 93.6) Pub Date : 2024-11-18 Deisy Ventura, Anne-Emanuelle Birn, Ruth Iguiñiz Romero, Michael Knipper
The Rio de Janeiro declarations chart possibilities in an era of inequity, war, climate change, and pandemics, but their shortfalls must be acknowledged, write Deisy Ventura and colleagues On 31 October 2024, the G20 health ministers met in Rio de Janeiro, Brazil, following a series of preparatory meetings held throughout 2024. A recent series in The BMJ suggested priorities for Brazil’s G20 leadership
-
Lack of abortion care is a threat to women’s health in Latin America BMJ (IF 93.6) Pub Date : 2024-11-18 Mercedes Colomar, Veronica Fiol
Inequalities and restrictions to sexual and reproductive health and rights are endangering women, write Mercedes Colomar and Veronica Fiol In 1994, the International Conference on Population and Development established a groundbreaking framework recognising reproductive rights as human rights.1 This framework prioritised people and human rights in development—rather than population control. Thirty
-
Inequities are not inevitable: tackling them can reduce maternal deaths BMJ (IF 93.6) Pub Date : 2024-11-18 Kirsty Kitchen
The latest MBRRACE-UK report on maternal mortality highlights action needed to prevent maternal deaths and reduce underlying inequities—especially for women who are migrants or known to social care, writes Kirsty Kitchen This year’s annual confidential inquiry on maternal deaths–MBRRACE saving lives, improving mothers’ care 2024–finds evidence of high levels of inequality and little progress.1 Many
-
Alastair Carruthers: dermatologist who pioneered cosmetic use of Botox in partnership with ophthalmologist wife Jean BMJ (IF 93.6) Pub Date : 2024-11-18 Rebecca Wallersteiner
Jean Carruthers, an ophthalmologist, came home from work one evening and told her dermatologist husband Alastair about a conversation she had had with a patient. As part of a clinical trial1 she was using botulinum toxin to treat patients with dystonia, an involuntary spasm of the eyelids. One of her patients had asked to be treated between her eyes. When Jean told the patient that she had not thought
-
Vaping and children’s oral health BMJ (IF 93.6) Pub Date : 2024-11-18 Daniel J Chivers
Mollet and colleagues discuss oral health in children.1 Due attention is paid to oral health as a component of the World Health Organization’s global strategy and action plan, including a focus on a “rights based approach” to motivate and challenge policy makers to tackle the root causes of poor oral health. Domestically, children’s …
-
Children’s right to oral health: other strategies needed for less democratic countries BMJ (IF 93.6) Pub Date : 2024-11-18 Anthony MacKenzie-Gureje
Mollet and colleagues call for a rights based approach to children’s oral health.1 There is an established link between poor oral health and lower socioeconomic status. Poor paediatric oral health is associated with education delay and increased morbidity in adulthood.2 Unfortunately, these associations are not new and have been known for at least 150 years. In 1905, James Kerr, a medical doctor, and
-
Children’s right to oral health: what about water fluoridation? BMJ (IF 93.6) Pub Date : 2024-11-18 Richard Turner
The editorial on children’s right to oral health mentions that 514 million children have untreated carious lesions in their primary teeth.1 It emphasises the importance of upstream policies such as reducing sugar consumption but makes no mention of water fluoridation. As Niger Carter, chief …
-
Solidarity kitchens: how pandemic food assistance developed to offer much more BMJ (IF 93.6) Pub Date : 2024-11-18 Rodrigo de Oliveira Andrade
A grassroots food assistance programme in Brazil that grew out of the pandemic is now trying to counter obesity and other diseases of poverty. Rodrigo de Oliveira Andrade reports “When the covid-19 pandemic began, I knew Brazil would face a battle against hunger,” says Adriana Salay Leme, a historian in the city of São Paulo. So when their restaurant was forced to shut during the pandemic, Leme and
-
G20 and the global south: opportunities for global health BMJ (IF 93.6) Pub Date : 2024-11-18 Maria de Lourdes Aguiar Oliveira, Natalie Mayet, Johanna Hanefeld, Anne Meierkord
Leadership by southern countries is focusing attention on health equity Countries in the Group of 20 (G20) represent two thirds of the world’s population, and it is a major forum for international cooperation. In recent years it has intensified its focus on global health, starting with the creation of a G20 health working group in 2017. The G20 presidency rotates annually. It is currently held by Brazil
-
Restructuring endometriosis care BMJ (IF 93.6) Pub Date : 2024-11-18 Prathiba M De Silva, Sharon Dixon, Ginisha Vekaria
Women need better coordination between primary and secondary care Endometriosis affects as many as 10% of women of reproductive age, or 190 million women globally.1 It can cause debilitating chronic pelvic pain and infertility, with treatment, work loss, and healthcare estimated to cost £12.5bn annually in the UK alone.2 The 2024 National Confidential Enquiry into Patient Outcome and Death (NCEPOD)
-
Non-hormonal management of vasomotor symptoms of menopause BMJ (IF 93.6) Pub Date : 2024-11-18 Sebastian Geraci, Satu Kuokkanen, Erika Banks
A new treatment option for women unable to take hormone replacement therapy Up to 80% of women experience vasomotor symptoms, including hot flushes and night sweats, during menopausal transition.1234567 These symptoms can persist for years before and after menopause, substantially impacting quality of life by impairing sleep, mood, and cognitive functioning.23456789101112 Approximately 32-46% of women
-
Unlocking NHS data requires public trust BMJ (IF 93.6) Pub Date : 2024-11-18 British Medical Journal Publishing Group
Katie Bramall-Stainer’s name was …
-
I don’t fit in at work, what should I do? BMJ (IF 93.6) Pub Date : 2024-11-18 Abi Rimmer
It’s natural to want to be included, but there are things you can do when you don’t feel part of the team, Abi Rimmer hears Kirsty Shires, salaried GP, GP appraiser, coach, and mentor, West Midlands, says, “For many of us, fitting in at work is important to our sense of self, identity, and belonging. When this is lacking, it can affect our confidence and ability to perform well—which in healthcare
-
Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-18 Barry Greenberg,Matthew Taylor,Eric Adler,Steven Colan,David Ricks,Paul Yarabe,Pavan Battiprolu,Gaurav Shah,Kinnari Patel,Matthew Coggins,Susanna Carou-Keenan,Jonathan D Schwartz,Joseph W Rossano
BACKGROUND Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the LAMP2 protein. In male patients, the predominant phenotype is progressive cardiac hypertrophy, cardiac dysfunction, and early death. There are no directed therapies for the disease. METHODS In this phase 1 study, we evaluated the safety and
-
Oral Infigratinib Therapy in Children with Achondroplasia. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-18 Ravi Savarirayan,Josep Maria De Bergua,Paul Arundel,Jean Pierre Salles,Vrinda Saraff,Borja Delgado,Antonio Leiva-Gea,Helen McDevitt,Marc Nicolino,Massimiliano Rossi,Maria Salcedo,Valerie Cormier-Daire,Mars Skae,Peter Kannu,John Phillips,Howard Saal,Paul Harmatz,Toby Candler,Dawn Hill,Elena Muslimova,Richard Weng,Yun Bai,Supriya Raj,Julie Hoover-Fong,Melita Irving,Daniela Rogoff
BACKGROUND Achondroplasia is a genetic skeletal condition that results in disproportionately short stature and medical complications throughout life. Infigratinib is an orally bioavailable FGFR1-3 selective tyrosine kinase inhibitor in development for achondroplasia. METHODS In this phase 2 dose-finding study, we evaluated the safety and efficacy of oral infigratinib in children with achondroplasia
-
NEJM at AHA - Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-18 Eric J Rubin,Jane Leopold,Stephen Morrissey
-
Gynaecologist is struck off for sexual harassment of colleague who was his patient. BMJ (IF 93.6) Pub Date : 2024-11-18 Clare Dyer
-
Antibiotic resistant infections in England surpass pre-pandemic levels. BMJ (IF 93.6) Pub Date : 2024-11-18 Brian Kennedy
-
Gynaecology clinicians demand urgent support to tackle lengthy waiting lists. BMJ (IF 93.6) Pub Date : 2024-11-18 Emma Wilkinson
-
NICE proposes adding cytisine as treatment option for smoking cessation. BMJ (IF 93.6) Pub Date : 2024-11-18 Jacqui Wise
-
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) JAMA (IF 63.1) Pub Date : 2024-11-18 Steven E. Nissen, Qiuqing Wang, Stephen J. Nicholls, Ann Marie Navar, Kausik K. Ray, Gregory G. Schwartz, Michael Szarek, Erik S. G. Stroes, Roland Troquay, Jannick A. N. Dorresteijn, Henry Fok, David A. Rider, Steven Romano, Kathy Wolski, Curtis Rambaran
ImportanceElevated lipoprotein(a) increases the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis.ObjectiveTo evaluate the effects of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), on lipoprotein(a) serum concentration.Design, Setting, and ParticipantsA multicenter trial in patients with stable ASCVD with serum lipoprotein(a) concentrations
-
Oral Muvalaplin for Lowering of Lipoprotein(a) JAMA (IF 63.1) Pub Date : 2024-11-18 Stephen J. Nicholls, Wei Ni, Grace M. Rhodes, Steven E. Nissen, Ann Marie Navar, Laura F. Michael, Axel Haupt, John H. Krege
ImportanceMuvalaplin inhibits lipoprotein(a) formation. A 14-day phase 1 study demonstrated that muvalaplin was well tolerated and reduced lipoprotein(a) levels up to 65%. The effect of longer administration of muvalaplin on lipoprotein(a) levels in individuals at high cardiovascular risk remains uncertain.ObjectivesTo determine the effect of muvalaplin on lipoprotein(a) levels and to assess safety
-
Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease-Reply. JAMA (IF 63.1) Pub Date : 2024-11-18 Brian Lipworth,Mintu Nath,Graham Devereux
-
Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial. JAMA (IF 63.1) Pub Date : 2024-11-18 Caihua Sang,Qiang Liu,Yiwei Lai,Shijun Xia,Ruhong Jiang,Songnan Li,Qi Guo,Qifan Li,Mingyang Gao,Xueyuan Guo,Lihong Huang,Nian Liu,Chenxi Jiang,Song Zuo,Xiaoxia Liu,Mengmeng Li,Weili Ge,Shangming Song,Lianghua Chen,Shuanglun Xie,Jiangang Zou,Ke Chen,Xiangfei Liu,Hesheng Hu,Xinhua Wang,Jinlin Zhang,Zhaojun Wang,Chi Wang,Liu He,Chao Jiang,Ribo Tang,Ning Zhou,Yunlong Wang,Deyong Long,Xin Du,Chenyang Jiang
Importance Success rates of pulmonary vein isolation (PVI) are modest for persistent atrial fibrillation (AF). Additional linear ablation beyond PVI has not been proved superior to PVI alone in randomized trials. Ethanol infusion of the vein of Marshall (EIVOM) facilitates ablation at the mitral isthmus and may lead to improved effectiveness of a linear ablation strategy. Objective To determine whether
-
Beyond Pulmonary Vein Isolation-Bringing Persistent Atrial Fibrillation in Line With Alcohol. JAMA (IF 63.1) Pub Date : 2024-11-18 Miguel Valderrábano
-
Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease. JAMA (IF 63.1) Pub Date : 2024-11-18 Chi-Kuei Hsu,Chih-Cheng Lai
-
Harm Reduction Strategies for People Who Use Drugs JAMA (IF 63.1) Pub Date : 2024-11-18 Ruchi V. Shah, Joseph Shay, Miriam Komaromy
This JAMA Insights explores harm reduction strategies for people who use drugs and the clinicians who treat them to help reduce the risk of unintentional drug overdose and infection.
-
Caregiver-Reported Quality in Hospices Owned by Private Equity Firms and Publicly Traded Companies JAMA (IF 63.1) Pub Date : 2024-11-18 Alexander E. Soltoff, Mark Aaron Unruh, David G. Stevenson, Dio Kavalieratos, Robert Tyler Braun
This study compares differences in caregiver-reported hospice quality across categories of ownership, including for-profit private equity firm (PEF)/publicly traded company (PTC)–owned and non-PEF/PTC–owned hospices as well as not-for-profit–owned hospices.
-
The US Preventive Services Task Force and Precision Prevention JAMA (IF 63.1) Pub Date : 2024-11-18 Michael J. Barry, Michael Silverstein, Wanda Nicholson
This Viewpoint summarizes how the US Preventive Services Task Force specifies target populations for its recommendations and highlights 3 problems—including exacerbation of health inequities—posed by the proposed use of more complex risk models to better identify target populations and increase effectiveness and efficiency of prevention efforts (“precision prevention”).
-
Diagnosis and Treatment of Polycythemia Vera JAMA (IF 63.1) Pub Date : 2024-11-18 Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas, Ronald Hoffman
ImportancePolycythemia vera (PV), a myeloproliferative neoplasm characterized by an increased red blood cell mass and increased risk of thrombosis, affects approximately 65 000 people in the US, with an annual incidence of 0.5 to 4.0 cases per 100 000 persons.ObservationsErythrocytosis (hemoglobin >16.5 mg/dL in men or >16.0 mg/dL in women) is a required diagnostic criterion, although thrombocytosis
-
Communication About Harm Reduction With Patients Who Have Opioid Use Disorder JAMA (IF 63.1) Pub Date : 2024-11-18 Mary Hawk, Raagini Jawa, Emma Sophia Kay
This JAMA Insights explores how clinicians can use the harm reduction communication framework to engage with patients who have opioid use disorder, which could help prevent overdose and other substance use–related harms.
-
Routine Spironolactone in Acute Myocardial Infarction. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-17 Sanjit S Jolly,Marc-André d'Entremont,Bertram Pitt,Shun Fu Lee,Rajibul Mian,Jessica Tyrwhitt,Sasko Kedev,Gilles Montalescot,Jan H Cornel,Goran Stanković,Raul Moreno,Robert F Storey,Timothy D Henry,Shamir R Mehta,Matthias Bossard,Petr Kala,Ravinay Bhindi,Biljana Zafirovska,P J Devereaux,John Eikelboom,John A Cairns,Madhu K Natarajan,J D Schwalm,Sanjib K Sharma,Wadea Tarhuni,David Conen,Sarah Tawadros
BACKGROUND Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is beneficial after myocardial infarction is uncertain. METHODS In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients with myocardial infarction who had undergone percutaneous
-
NEJM at AHA - Routine Spironolactone in Acute Myocardial Infarction. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-17 Eric J Rubin,Jane Leopold,Stephen Morrissey
-
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial Nat. Med. (IF 58.7) Pub Date : 2024-11-15 Steven M. Horwitz, Ajit J. Nirmal, Jahan Rahman, Ran Xu, Esther Drill, Natasha Galasso, Nivetha Ganesan, Theresa Davey, Helen Hancock, Leslie Perez, Catherine Maccaro, Alexandra Bahgat, Evan Marzouk, Elizabeth Cathcart, Alison Moskowitz, Ariela Noy, Anita Kumar, Eric Jacobsen, David C. Fisher, Neha Mehta-Shah, Youn H. Kim, Michael Khodadoust, Nikita Kotlov, Anastasia Nikitina, Olga Kudryashova, Valeria
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03076-6, published online 17 June 2024.
-
When I use a word . . . Academic fraud—the Darsee Affair BMJ (IF 93.6) Pub Date : 2024-11-15 Jeffrey K Aronson
Fraudulent academic activities that I have referred to as “felonies” comprise fabrication (defined by the US Office of Research Integrity as “making up data or results and recording or reporting them”), falsification (“manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record”), and plagiarism
-
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Marianna Fontana,Scott D Solomon,Jessica Kachadourian,Liron Walsh,Ricardo Rocha,David Lebwohl,Derek Smith,Jörg Täubel,Edward J Gane,Björn Pilebro,David Adams,Yousuf Razvi,Joy Olbertz,Alexandra Haagensen,Peijuan Zhu,Yuanxin Xu,Adia Leung,Alison Sonderfan,David E Gutstein,Julian D Gillmore
BACKGROUND Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) targeting the gene encoding transthyretin (TTR). METHODS In this phase 1, open-label trial, we administered a single intravenous